---

Chronic Obstructive Pulmonary Disease (COPD) - Comprehensive Review

---

1. Definition

• Emphysema - destruction of alveolar walls and air space enlargement
• Chronic Bronchitis - defined clinically as a productive cough for at least 3 consecutive months in each of 2 consecutive years

---

2. Epidemiology

• 3rd most common cause of death in the United States
• Accounts for over $40 billion/year in direct and indirect healthcare costs
• Traditionally under-diagnosed, especially in women
• Once thought to affect only 15-30% of smokers; radiographic studies now show important progressive bronchial wall thickening and lung tissue loss even in smokers with normal spirometry
• Katzung's Basic and Clinical Pharmacology, 16th Ed.

---

3. Etiology and Risk Factors

---

4. Pathogenesis and Pathology

4a. Emphysema

• Mechanism: Cigarette smoke activates macrophages and neutrophils, releasing elastases (particularly neutrophil elastase) and matrix metalloproteinases (MMPs). These proteases overwhelm the normal anti-protease defenses (alpha-1 antitrypsin, SLPI).
• The protease-antiprotease imbalance destroys alveolar walls and elastic support structures.
• Loss of elastic recoil leads to air trapping and hyperinflation.

• Centriacinar (centrilobular) - most common; affects the respiratory bronchioles and central acinus; strongly associated with cigarette smoking; predominantly affects upper lobes
• Panacinar (panlobular) - uniform involvement of the entire acinus; characteristic of A1AT deficiency; predominantly affects lower lobes
• Paraseptal (distal acinar) - adjacent to pleura and septa; associated with spontaneous pneumothorax in young adults

• Robbins & Kumar Basic Pathology

4b. Chronic Bronchitis

• Mechanism: Chronic irritant exposure leads to hypertrophy and hyperplasia of tracheal/bronchial submucosal mucous glands (measured by the Reid index: gland thickness/total wall thickness; normal <0.4; chronic bronchitis >0.5).
• Goblet cell metaplasia in small airways further increases mucus production.
• Small airway inflammation (chronic bronchiolitis) and fibrosis cause obstruction.
• Impaired mucociliary clearance leads to persistent airway infection, especially with Haemophilus influenzae.

4c. The Role of Inflammation

---

5. Pathophysiology

Airflow Obstruction

• Reduced FEV1 with FEV1/FVC ratio < 0.7 (post-bronchodilator, per GOLD)
• Loss of elastic recoil (emphysema) + increased airway resistance (bronchitis/bronchiolitis)
• FVC is typically preserved or reduced less than FEV1 (obstructive pattern)

Lung Hyperinflation

• Static hyperinflation: Increased lung compliance in emphysema elevates the relaxation volume (functional residual capacity).
• Dynamic hyperinflation: During exercise, insufficient expiratory time causes air trapping and rising end-expiratory lung volume (EELV). This erodes the inspiratory reserve volume (IRV), causes dyspnea ("neuromechanical uncoupling"), and impairs cardiac function. - Fishman's Pulmonary Diseases

Gas Exchange Abnormalities

• V/Q mismatch: Areas of low V/Q (collapsed/mucus-plugged alveoli with intact perfusion) cause hypoxemia.
• In advanced disease: hypoxemia (low PaO2) and hypercapnia (elevated PaCO2), indicating ventilatory failure.
• "Blue bloater" (chronic bronchitis dominant): cyanosis, hypoxemia, hypercapnia, cor pulmonale, peripheral edema
• "Pink puffer" (emphysema dominant): pursed-lip breathing, barrel chest, dyspnea, relatively preserved oxygenation at rest

Cor Pulmonale

• Chronic hypoxia causes pulmonary vasoconstriction and pulmonary hypertension.
• Right ventricular hypertrophy and eventually right heart failure (cor pulmonale) ensues.
• Clinically: elevated JVP, peripheral edema, RV heave.

---

6. Clinical Features

Symptoms

• Dyspnea - initially on exertion, progressing to rest
• Chronic productive cough - especially morning cough with sputum
• Wheezing - particularly during exacerbations
• Fatigue, weight loss in advanced disease

Signs

• Barrel chest - increased AP diameter from hyperinflation
• Diminished breath sounds with prolonged expiration
• Pursed-lip breathing - to maintain positive end-expiratory pressure
• Use of accessory muscles of respiration
• Cyanosis in advanced disease
• Asterixis in CO2 narcosis
• Clubbing - not characteristic of COPD alone; presence should prompt search for lung cancer or bronchiectasis

---

7. Diagnosis

Spirometry (Definitive)

• Post-bronchodilator FEV1/FVC < 0.7 confirms airflow obstruction
• 2025 GOLD update: Pre-bronchodilator FEV1/FVC > 0.7 can be used to rule out COPD (avoiding unnecessary post-bronchodilator testing), unless a "volume responder" is suspected (low FEV1 or high symptom burden). If pre-BD FEV1/FVC < 0.7, post-bronchodilator confirmation is still needed.

GOLD Grading of Airflow Obstruction (post-BD FEV1 % predicted)

Symptom Assessment Tools

• mMRC Dyspnea Scale (0-4) - higher score = more breathless
• CAT (COPD Assessment Test) - 8-item questionnaire; score 0-40

GOLD ABE Assessment Tool (2023 onward)

• Group A: Low exacerbation risk (0-1/year, no hospitalization) + fewer symptoms (mMRC 0-1 or CAT < 10)
• Group B: Low exacerbation risk + more symptoms (mMRC ≥2 or CAT ≥10)
• Group E: High exacerbation risk (≥2 exacerbations/year OR ≥1 requiring hospitalization)

Additional Investigations

• Chest X-ray: Hyperinflation, flat diaphragm, increased retrosternal airspace, bullae
• CT thorax: Best for quantifying emphysema distribution and airway disease; guides surgical decisions
• ABG: Hypoxemia ± hypercapnia in moderate-severe disease
• Alpha-1 antitrypsin level: Screen all patients with COPD (especially < 45 years, non-smokers, lower lobe predominance)
• Pulse oximetry: SpO2 to screen for need for long-term oxygen therapy (LTOT)
• 6-Minute Walk Test: Exercise capacity and prognosis
• ECG/Echocardiogram: Assess for cor pulmonale and pulmonary hypertension

---

8. Management

8a. Non-Pharmacological

• Smoking cessation - most effective intervention to slow FEV1 decline; reduces exacerbation rate
• Pulmonary rehabilitation - improves dyspnea, exercise capacity, and quality of life in all patients with MRC ≥ 3
• Vaccinations: Influenza (annual), pneumococcal, COVID-19, RSV (per 2025 GOLD); shown to reduce exacerbations
• Nutritional support: Malnutrition common in severe COPD; worsens prognosis
• Reducing occupational/environmental exposures
• Virtual reality-complemented pulmonary rehabilitation: Emerging evidence - a 2025 systematic review (PMID 40193185) found improvements in lung function, exercise capacity, and dyspnea scores

8b. Pharmacological Management

Bronchodilators (Cornerstone of Therapy)

• SABA (e.g., albuterol/salbutamol) - rapid relief of dyspnea
• SAMA (e.g., ipratropium bromide) - anticholinergic; can combine with SABA for additive effect

• LABA (e.g., salmeterol, formoterol, indacaterol) - twice or once daily; reduce dyspnea and exacerbations
• LAMA (e.g., tiotropium, umeclidinium, aclidinium) - once daily; superior to LABA alone for preventing exacerbations; reduces hyperinflation

Inhaled Corticosteroids (ICS)

• Do NOT use as monotherapy in COPD
• Recommended only with LABA (as LABA/ICS) or in triple therapy (LABA/LAMA/ICS)
• Use guided by blood eosinophil count:
  • Eosinophils < 100 cells/µL: ICS unlikely to benefit
  • Eosinophils 100-300 cells/µL: Consider with history of exacerbations
  • Eosinophils > 300 cells/µL: ICS likely to benefit
• Risk: Increased risk of pneumonia with ICS, especially fluticasone
• Katzung's Basic and Clinical Pharmacology

Triple Therapy (LABA + LAMA + ICS)

• Superior to LABA/ICS for exacerbation prevention, lung function, and quality of life
• A post-hoc analysis (referenced in 2025 GOLD) showed triple therapy reduces cardiovascular events vs. LAMA/LABA, likely through exacerbation prevention

Phosphodiesterase-4 Inhibitors

• Roflumilast - oral, selective PDE4 inhibitor; reduces exacerbation frequency; indicated in severe COPD with chronic bronchitis phenotype and frequent exacerbations; add-on to bronchodilators

Methylxanthines

• Theophylline - low-dose; modest bronchodilation, anti-inflammatory properties; narrow therapeutic window; large randomized trial failed to show benefit on exacerbation frequency; now rarely recommended
• Katzung's Basic and Clinical Pharmacology

Antibiotics (Prophylactic)

• Azithromycin - reduces exacerbation frequency in selected patients (former smokers, elderly, moderate-severe COPD); risk of hearing loss and QT prolongation; monitor ECG and culture for MAC

8c. Initial Pharmacological Treatment (GOLD 2025/2026)

8d. Long-Term Oxygen Therapy (LTOT)

• Indicated if PaO2 ≤ 55 mmHg OR SpO2 ≤ 88% at rest (on two measurements 3 weeks apart)
• Or PaO2 55-60 mmHg with evidence of cor pulmonale, polycythemia, or right heart failure
• Target SpO2: 88-92% (avoid hyperoxia which can worsen hypercapnia)
• Minimum 15-18 hours/day to improve survival

8e. Oxygen in Exacerbations

• Controlled O2 therapy targeting SpO2 88-92% (not 94-98% as in non-COPD)
• Excessive O2 risks Haldane effect and worsening hypercapnia

8f. Ventilatory Support

• NIV (BiPAP): Preferred for acute hypercapnic respiratory failure (pH < 7.35 and PaCO2 > 45 mmHg)
• Reduces intubation rate and mortality in acute exacerbations
• Invasive ventilation (IMV): When NIV fails or contraindicated

8g. Surgical/Interventional

• Lung Volume Reduction Surgery (LVRS): In upper-lobe predominant emphysema with poor exercise capacity; improves survival in selected patients (NETT trial)
• Bronchoscopic lung volume reduction: Endobronchial valves (Zephyr, Spiration); reduces hyperinflation; good option when collateral ventilation absent
• Lung transplantation: Selected severe COPD patients; improves quality of life; survival benefit mainly in emphysema with A1AT deficiency

---

9. Acute Exacerbations of COPD (AECOPD)

Triggers

• Viral infections (Rhinovirus, influenza, RSV) - most common (~50-70%)
• Bacterial infections (H. influenzae, S. pneumoniae, M. catarrhalis)
• Air pollution, cold weather, pulmonary embolism

Management

• Bronchodilators: Increase dose/frequency of SABA ± SAMA (nebulized in severe cases)
• Systemic corticosteroids: Prednisolone 40 mg/day for 5 days - reduces recovery time, risk of treatment failure, hospital stay
• Antibiotics: Recommended when there is change in sputum color/purulence, increased dyspnea AND sputum volume (Anthonisen criteria); beta-lactams, doxycycline, or azithromycin active against H. influenzae
• Controlled oxygen: SpO2 88-92%
• NIV: For acute hypercapnic respiratory failure
• Prognosis: Mortality of AECOPD is greater than asthma exacerbations due to older age and comorbidities (especially cardiovascular disease)
• Katzung's Basic and Clinical Pharmacology

---

10. Complications and Comorbidities

---

11. Prognosis

---

12. GOLD 2025/2026 Updates (Key Changes)

1. Spirometry: Pre-bronchodilator FEV1/FVC > 0.7 can rule out COPD in most patients (reduces unnecessary testing). "Volume responders" still need post-BD spirometry.
2. ICS guidance: Blood eosinophil count formally integrated into decision to add ICS.
3. Triple therapy cardiovascular benefit: New evidence showing reduced CV events with LABA/LAMA/ICS vs. dual bronchodilation.
4. New section on cardiovascular risk: Proactive assessment and intervention recommended.
5. New section on climate change and COPD: Extreme heat and cold both increase COPD mortality; cold carries greater risk.
6. COPD etiotypes: New taxonomy recognizing diverse pathways to COPD (COPD-G for genetic, COPD-D for dysmorphic lung, COPD-N for normal aging, etc.) beyond just smoking-related disease.

---

Summary Table

---